NRx Pharmaceuticals, Inc. (NRXPW) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

NRx Pharmaceuticals, Inc. (NRXPW) Healthcare & Pipeline Overview

NRx Pharmaceuticals, Inc. is a clinical-stage biotechnology firm based in Wilmington, Delaware, focused on developing novel therapeutics for central nervous system disorders and life-threatening pulmonary diseases. Its pipeline includes ZYESAMI for COVID-19 respiratory failure and NRX-100/NRX-101 for bipolar depression with suicidal ideation, addressing critical unmet medical needs.

What Is the Investment Thesis for NRXPW?

NRx Pharmaceuticals, Inc. presents an investment profile typical of a clinical-stage biotechnology company, characterized by high potential upside contingent on successful drug development and significant inherent risks. The company's pipeline, featuring ZYESAMI for COVID-19 related respiratory failure and NRX-100/NRX-101 for bipolar depression with suicidal ideation, targets areas with substantial unmet medical needs. The completion of a Phase IIb/III study for ZYESAMI indicates progress towards potential regulatory submission, while the CNS programs address critical mental health challenges. With a market capitalization of $0.00B and a profit margin of -1070.3%, the company is currently pre-revenue, reflecting its intensive R&D phase. The high Beta of 2.02 suggests considerable stock price volatility, which is common for early-stage biotechs. Future value drivers are intrinsically linked to positive clinical trial outcomes, successful regulatory approvals, and eventual commercialization or strategic partnerships for its drug candidates. The ability to secure further funding to advance its pipeline through pivotal trials will be crucial for its long-term viability and growth.

Based on FMP financials and quantitative analysis

NRXPW Key Highlights

NRx Pharmaceuticals, Inc. currently holds a market capitalization of $0.00B, reflecting its early-stage development and pre-revenue status.

• The company reported a significant negative profit margin of -1070.3%, indicative of substantial investments in research and development typical for a clinical-stage biotechnology firm.
• A gross margin of 37.1% suggests that, if commercialized, the company's products could yield a healthy margin on production costs, although this metric is less relevant for a pre-revenue company.
• NRXPW exhibits a Beta of 2.02, indicating that its stock price is significantly more volatile than the broader market, a common characteristic of biotechnology companies with binary clinical trial outcomes.
• The company does not currently pay a dividend, consistent with its growth-oriented strategy and need to reinvest capital into its drug development pipeline.

Who Are NRXPW's Competitors?

NRXPW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are NRXPW's Key Strengths?

Focused pipeline addressing high-unmet medical needs in CNS disorders and life-threatening pulmonary diseases.

• Progressed lead candidate ZYESAMI through a Phase IIb/III clinical study, indicating advanced development.
• Specialized therapeutic focus on bipolar depression with suicidal ideation (NRX-100, NRX-101) targets a critical patient population.
• Relatively lean operational structure with 10 employees, potentially allowing for agility in R&D.

What Are NRXPW's Weaknesses?

Clinical-stage company with no commercialized products and thus no current revenue, leading to significant negative profit margins.

• High dependence on successful clinical trial outcomes and regulatory approvals for future viability and revenue generation.
• Small employee base of 10 may limit the scope and speed of multiple parallel development programs.
• Significant capital requirements for R&D and clinical trials, necessitating ongoing funding efforts.

What Could Drive NRXPW Stock Higher?

NRXPW catalyst: Announcement of top-line data or full results from the completed Phase IIb/III clinical study of ZYESAMI for COVID-19 related respiratory failure, expected in 2026.

• Potential submission of a New Drug Application (NDA) or Emergency Use Authorization (EUA) for ZYESAMI, contingent on positive clinical data and regulatory guidance, anticipated in late 2026 or early 2027.
• Progress updates or initiation of pivotal Phase III clinical trials for NRX-100 or NRX-101 for bipolar depression with suicidal ideation, expected within the next 12-18 months.
• Formation of strategic partnerships or licensing agreements for its pipeline assets, which could provide non-dilutive funding and expand development capabilities.

What Are the Key Risks for NRXPW?

Financial-distress signal — its Altman Z-Score of -15.47 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or unexpected safety concerns for ZYESAMI, NRX-100, or NRX-101, which could halt development and result in significant financial losses.
• Inability to secure sufficient additional funding to complete ongoing clinical trials and advance drug candidates through regulatory approval, risking delays or discontinuation of programs.
• Intense competition from other pharmaceutical and biotechnology companies developing treatments for COVID-19 complications, CNS disorders, and mental health conditions.
• Regulatory setbacks, including delays in approval, unfavorable review outcomes, or stringent post-marketing requirements from health authorities.
• High cash burn rate typical of clinical-stage biotechs, leading to ongoing dilution risk from equity financing or increased debt burden.

What Are the Growth Opportunities for NRXPW?

• Growth opportunity 1: Successful Regulatory Approval and Commercialization of ZYESAMI. ZYESAMI, having completed a Phase IIb/III clinical study for COVID-19 related respiratory failure, represents a significant near-to mid-term growth driver. If NRx Pharmaceuticals secures regulatory approval for ZYESAMI, it could tap into a market that, while evolving, still faces needs for severe respiratory illness treatments. The global market for COVID-19 therapeutics has been substantial, and while initial pandemic urgency has shifted, a proven treatment for severe respiratory complications could still command significant market share. The timeline for this opportunity would depend on regulatory review processes, potentially within the next 1-3 years if data supports approval, offering a pathway to initial revenue generation.
• Growth opportunity 2: Advancement and Approval of NRX-100 for Bipolar Depression with Acute Suicidal Behavior/Ideation. NRX-100 targets a critical and underserved patient population: individuals with bipolar depression experiencing acute suicidal ideation or behavior. The market for mental health therapeutics, particularly for severe and life-threatening conditions, is substantial and growing. Current treatments often have limitations in efficacy or side effect profiles for this specific high-risk group. If NRX-100 successfully navigates clinical trials and gains regulatory approval, it could establish NRx Pharmaceuticals as a leader in a niche but high-impact segment of psychiatric care. This represents a significant growth opportunity over the next 3-5 years, contingent on clinical success.
• Growth opportunity 3: Development and Market Penetration of NRX-101 for Sub-Acute Suicidal Ideation and Behavior. Complementing NRX-100, NRX-101 addresses sub-acute suicidal ideation and behavior in bipolar depression. This broader patient population, while not in immediate crisis, still requires effective interventions to prevent escalation. The total addressable market for bipolar depression treatments is considerable, estimated to be in the tens of billions globally. A differentiated therapeutic like NRX-101 could capture a significant portion of this market by offering a targeted solution. The timeline for this opportunity is likely mid-to-long term, 4-7 years, as it progresses through clinical development, but it holds substantial revenue potential.
• Growth opportunity 4: Expansion of Pipeline into New Central Nervous System (CNS) Indications. NRx Pharmaceuticals' expertise in CNS disorders, demonstrated by its NRX-100 and NRX-101 programs, positions it for potential expansion into other high-need neurological or psychiatric conditions. Leveraging its research platforms and scientific understanding, the company could identify and develop new drug candidates for conditions such as other mood disorders, anxiety disorders, or neurodegenerative diseases. The global CNS therapeutics market is vast and continually growing, driven by aging populations and increasing prevalence of mental health issues. This long-term growth opportunity, spanning 5-10 years, would diversify the company's risk and broaden its market reach.
• Growth opportunity 5: Strategic Partnerships and Licensing Agreements. As a clinical-stage company with a focused pipeline, NRx Pharmaceuticals has the opportunity to engage in strategic partnerships, collaborations, or licensing agreements with larger pharmaceutical companies. Such agreements can provide non-dilutive funding, leverage larger companies' commercialization infrastructure, and accelerate market access for its drug candidates. For instance, a partnership for ZYESAMI or its CNS assets could provide immediate capital and expertise for late-stage development or global distribution. This strategy could significantly de-risk its development programs and unlock value, with potential agreements emerging at various stages of clinical development over the next 1-5 years.

What Threats Does NRXPW Face?

• Clinical trial failures or unexpected adverse events for any of its drug candidates.
• Inability to secure necessary regulatory approvals from health authorities.
• Intense competition from larger pharmaceutical companies and other biotech firms developing similar treatments.
• Challenges in securing adequate funding to sustain R&D and clinical operations.
• Market acceptance issues or lower-than-expected demand for approved products.

What Are NRXPW's Competitive Advantages?

• Proprietary drug candidates (ZYESAMI, NRX-100, NRX-101) protected by intellectual property, including patents.
• Specialized focus on high-need therapeutic areas like acute suicidal ideation in bipolar depression, potentially leading to first-in-class or best-in-class treatments.
• Accumulated clinical data and expertise from ongoing and completed Phase IIb/III studies, creating a barrier to entry for competitors.
• Regulatory exclusivity periods granted upon drug approval, providing a temporary monopoly for commercialized products.

What Does NRXPW Do?

NRx Pharmaceuticals, Inc., founded in 2015 and headquartered in Wilmington, Delaware, operates as a clinical-stage pharmaceutical company dedicated to addressing significant unmet medical needs through the development of novel therapeutics. The company's strategic focus encompasses two critical areas: central nervous system (CNS) disorders and life-threatening pulmonary diseases. As a clinical-stage entity, NRx Pharmaceuticals is primarily engaged in research and development, advancing its drug candidates through various phases of clinical trials to demonstrate their safety and efficacy. Its pipeline features several key investigational products. One prominent candidate is ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for the treatment of COVID-19 related respiratory failure. This program represents the company's efforts to contribute to solutions for severe acute respiratory conditions. Beyond pulmonary indications, NRx Pharmaceuticals has a strong emphasis on mental health, particularly within the challenging landscape of bipolar depression. The company is developing NRX-100, an oral therapeutic specifically designed for the treatment of bipolar depression in patients experiencing acute suicidal behavior or ideation. This drug candidate aims to provide a much-needed intervention for a patient population at high risk. Complementing NRX-100, the company is also advancing NRX-101, another oral therapeutic targeting sub-acute suicidal ideation and behavior in individuals with bipolar depression. Both NRX-100 and NRX-101 underscore NRx Pharmaceuticals' commitment to developing innovative treatments for complex psychiatric conditions, where existing therapies may have limitations or fail to adequately address suicidal ideation. The company's operational model is centered on rigorous scientific research, clinical development, and navigating the stringent regulatory pathways required for drug approval, positioning it within the highly specialized and capital-intensive biotechnology sector.

What Products and Services Does NRXPW Offer?

• Develops novel therapeutics for central nervous system (CNS) disorders.
• Develops novel therapeutics for life-threatening pulmonary diseases.
• Advances ZYESAMI, an investigational drug, for COVID-19 related respiratory failure, having completed Phase IIb/III clinical studies.
• Develops NRX-100, an oral therapeutic for bipolar depression with acute suicidal behavior/ideation.
• Develops NRX-101, an oral therapeutic for bipolar depression with sub-acute suicidal ideation and behavior.
• Engages in clinical research and development to bring new pharmaceutical products to market.
• Focuses on addressing significant unmet medical needs in specialized therapeutic areas.

How Does NRXPW Make Money?

• Primarily a research and development (R&D) focused entity, investing in the discovery and clinical advancement of drug candidates.
• Future revenue generation is contingent upon successful clinical trials, regulatory approvals, and subsequent commercialization of its investigational drugs.
• Potential for revenue through licensing agreements or partnerships with larger pharmaceutical companies for development or commercialization rights.
• Operates on a capital-intensive model, requiring significant funding for ongoing clinical trials and R&D activities.

What Industry Does NRXPW Operate In?

NRx Pharmaceuticals, Inc. operates within the highly specialized and dynamic biotechnology industry, a sub-sector of Healthcare. This industry is characterized by intensive research and development, long development cycles, and significant regulatory hurdles. Clinical-stage companies like NRx Pharmaceuticals are at the forefront of innovation, aiming to discover and develop novel therapeutics for diseases with high unmet medical needs. The competitive landscape is intense, with numerous pharmaceutical and biotechnology firms vying for breakthroughs in specific therapeutic areas. NRx Pharmaceuticals' focus on central nervous system disorders and life-threatening pulmonary diseases places it in segments that attract substantial R&D investment due to the high burden of these conditions globally. Success in this industry is largely driven by intellectual property, positive clinical trial results, and the ability to navigate complex regulatory approval processes, making it a high-risk, high-reward environment where scientific innovation is paramount.

Who Are NRXPW's Key Customers?

• Future patients suffering from central nervous system disorders, specifically bipolar depression with suicidal ideation.
• Future patients experiencing life-threatening pulmonary diseases, such as COVID-19 related respiratory failure.
• Healthcare providers (physicians, hospitals) who would prescribe or administer the company's approved therapeutics.
• Potentially, larger pharmaceutical companies interested in licensing or acquiring rights to its drug candidates.

Return on equity for NRx Pharmaceuticals, Inc. stands at 168.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -68.7%, showing how much profit it generates from its asset base. Its free cash flow yield is -35.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -18.7%, the inverse of the P/E and a quick read on earnings relative to price.

NRx Pharmaceuticals, Inc. (NRXPW) Valuation Context

Relative to its peer group, NRXPW's quantitative score of 49/100 is below the peer average of 71/100.

Company Profile

NRx Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Wilmington, US. The company is led by CEO Jonathan C. Javitt. NRXPW has traded publicly since 2017.

NRx Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.47 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project NRx Pharmaceuticals, Inc. revenue of about $85.9M for fiscal 2026, with EPS near $0.53.

NRXPW Financials

NRXPW Latest News

NRXPW Analyst Consensus

NRXPW MoonshotScore

What Investors Ask About NRx Pharmaceuticals, Inc. (NRXPW) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources